Sage Therapeutics Inc’s recently made public that its Officer JONAS JEFFREY M acquired Company’s shares for reported $41441.0 on Dec 10 ’24. In the deal valued at $5.53 per share,7,500 shares were bought.
A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in late November from “an Underperform” to “a Sector perform”. RBC Capital Mkts revised its rating on October 04, 2024. It rated SAGE as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of SAGE
On Tuesday, Sage Therapeutics Inc [NASDAQ:SAGE] saw its stock fall -2.07% to $6.61. Over the last five days, the stock has lost -3.64%. Sage Therapeutics Inc shares have risen nearly 21.73% since the year began. Nevertheless, the stocks have fallen -46.43% over the past one year. While a 52-week high of $13.47 was reached on 03/28/25, a 52-week low of $4.62 was recorded on 01/02/25. SMA at 50 days reached $7.50, while 200 days put it at $7.13.
Levels Of Support And Resistance For SAGE Stock
The 24-hour chart illustrates a support level at 6.53, which if violated will result in even more drops to 6.45. On the upside, there is a resistance level at 6.74. A further resistance level may holdings at 6.88. The Relative Strength Index (RSI) on the 14-day chart is 35.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.54, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.74%. Stochastics %K at 9.24% indicates the stock is a buying.
